Abbott (NYSE:ABT) landed an FDA panel date to review its MitraClip aortic valve repair system, according to an FDA notice.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Boston Scientific launches Promus Premier stent in Europe
Boston Scientific (NYSE:BSX) said it plans to immediately launch its Promus Premier drug-eluting stent across the pond, now that the European Union has given the device CE Mark approval.
Direct Flow aims to use heart valve giants’ experience against them
Being one of the smallest players on the field means you’ve got to differentiate yourself to stand out against the titans of the game, and that’s what Direct Flow Medical CEO Bernie Lyons aims to do.
St. Jude revisits RESPECT trial, touts signs of benefits of Amplatzer device
Medical device giant St. Jude Medical (NYSE:STJ) resurrected data from its failed RESPECT study, touting additional analyses and benefits of its Amplatzer patent foramen ovale closure device.
Researchers find a genetic marker for aortic valve disease
A team of researchers have pinpointed a gene that may be responsible for double a patient’s risk of calcium buildup in the aortic valve, a condition linked with heart failure, stroke and sudden cardiac death.
The finding may lead to new research and therapies, which are very limited for patients with narrowing, or stenosis, of the aortic valve.
Edwards Lifesciences posts Q4, 2012 gains, confirms guidance
Edwards Lifesciences (NYSE:EW) handily beat Wall Street’s expectations for its 4th-quarter and 2012 profits and confirmed its outlook for 2013 today after the market’s close.
Medtronic lands Euro win for next-gen heart implants
St. Jude expands European TAVI trial to include larger valves
St. Jude Medical (NYSE:STJ) researchers implanted the 1st patient with a larger-sized Portico transcatheter aortic valve as part of the medical device maker’s ongoing Portico TF EU trial.
Boston Scientific hits 52-week high
Boston Scientific (NYSE:BSX) shares hit a 52-week high 2 days ago and are flirting with another today, as investors react to strong 4th-quarter and 2012 results.
The Marlborough, Mass.-based medical device company’s stock hit $7.43 per share Jan. 29, the day it announced its financial numbers. Shares had fallen as low as $4.79 apiece during the last 52 weeks.
Svelte Medical launches drug-eluting stent trial
Svelte Medical said it launched the Direct II Phase II clinical trial of its drug-eluting stent comparing the device with Medtronic‘s (NYSE:MDT) Resolute DES.
The Svelte device elutes the anti-stenosis drug sirolimus using a bioabsorbable carrier made of amino acids, unlike the polymer-based drug carrier used in the Resolute stent.
Direct Flow lands Euro win for TAVI system
California-based medical device maker Direct Flow Medical touted European regulatory approval for its transcatheter aortic valve implantation system, which the company says "virtually eliminates aortic regurgitation."
The device touts a metal-free frame and a low-profile delivery system, as well as a double-ring design that is both repositionable and retrievable after full deployment.